幽门螺杆菌感染、检验和药物开发的研究进展

Research Progress of Helicobacter Pylori Infection, Testing and Drug Development

幽门螺杆菌与慢性胃炎、消化性溃疡、胃癌等消化道疾病等密切相关,它被归类为第一类致癌物。流行病学调查结果显示幽门螺杆菌感染了全球超过一半的人群。治疗Hp的指南共识在不断地被更新,但抗生素的选择并未有重大突破,并且存在药物不良反应、消化道不适、肠道菌群失调等问题。我们可从祖国医学、肠道微生态等方面研究,寻找以抗生素为基础的治疗上辅助根除Hp的新策略。

Helicobacter pylori is closely related to chronic gastritis, peptic ulcer, gastric cancer and other digestive tract diseases. It is classified as the first category of carcinogens. Epidemiological survey results show that Helicobacter pylori has infected more than half of the world’s population. The consensus on the guidelines for the treatment of Hp is constantly being updated, but there has not been a major breakthrough in the choice of antibiotics, and there are problems such as adverse drug reactions, gastrointestinal discomfort, and intestinal flora imbalance. We can study from the aspects of motherland medicine, intestinal microecology,etc., to find new strategies for the eradication of H. pylori based on antibiotics.